FIELD: medicine.
SUBSTANCE: there is offered application of humanised fused protein for making a medicine used for stimulation of immune response and stabilisation of disease progressing in patients with GD2-positive tumours. The antibody contains antibody H14.18 caught with surface glycosphingolipid GD2 of human cells, and cytokine IL2. There is disclosed method of increase in ADCC and lysis activity of natural killers in cancer patients by introduction of the fused protein. The invention can be applied in GD2-overexpression cancer therapy.
EFFECT: application of the invention provides low-immunogenicity antibody.
2 cl, 8 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-AFFINITY ANTI-GD2 ANTIBODIES | 2014 |
|
RU2680267C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| RECOMBINANT SPECIFIC ANTIBODY (VARIANTS) AND USES THEREOF | 2002 |
|
RU2306320C9 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| ANTIBODIES TO OX-2/CD200 AND THEIR APPLICATION | 2007 |
|
RU2520088C2 |
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| ANTIBODIES TO H7CR | 2013 |
|
RU2691428C2 |
| ANTIBODIES TO H7CR | 2013 |
|
RU2650756C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
